scispace - formally typeset
K

Kerry N L Avery

Researcher at University of Bristol

Publications -  116
Citations -  6105

Kerry N L Avery is an academic researcher from University of Bristol. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 33, co-authored 100 publications receiving 5012 citations. Previous affiliations of Kerry N L Avery include National Institute for Health Research & Medical Research Council.

Papers
More filters
Journal ArticleDOI

ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.

TL;DR: To develop and evaluate the International Consultation on Incontinence Questionnaire (ICIQ), a new questionnaire to assess urinary incontinence and its impact on quality of life (QoL).
Journal ArticleDOI

The International Consultation on Incontinence Modular Questionnaire: www.iciq.net

TL;DR: The ICIQ can offer a full range of urinary tract symptom questionnaires and the development of the ICIQ website is anticipated to be crucial for informing potential users of the phase of development of all ICIQ modules.
Journal ArticleDOI

Comparison of two questionnaires for assessing the severity of urinary incontinence: The ICIQ-UI SF versus the incontinence severity index.

TL;DR: It is proposed to propose intervals for four severity levels of ICIQ‐UI SF and to compare the International Consultation on Incontinence Questionnaire‐Urinary incontinence Short Form with the Incontinent Severity Index (ISI).
Journal ArticleDOI

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

TL;DR: The effect of the adverse events within 35 days of transrectal ultrasound guided biopsy from the perspective of asymptomatic men having prostate specific antigen (PSA) testing was measured to assess early attitude to re-biopsy and to estimate healthcare resource use associated with adverse events due to biopsy to develop a classification scheme for reporting adverse events after prostate biopsy.